Gilead Sciences Inc. Advances Long‑Acting HIV Prevention and Prepares for a Major CAR‑T Expansion
Gilead Sciences (Nasdaq: GILD) reported compelling evidence that its once‑yearly HIV pre‑exposure prophylaxis (PrEP) agent, lenacapavir, delivers markedly superior persistence compared with the standard daily oral therapy emtricitabine/tenofovir disoproxil fumarate (F/TDF). In the multinational PURPOSE 5 trial, 85.6 % of participants who received the twice‑yearly injectable formulation remained adherent through week 52, versus 46.3 % for those on daily F/TDF (p < 0.0001). No HIV acquisitions were recorded in the lenacapavir cohort, and discontinuation due to adverse events was negligible. The data will be presented at HIV Glasgow 2026 and underscore lenacapavir’s potential to address the long‑standing challenge of patient adherence in PrEP.
In parallel, Gilead’s oncology and cell‑therapy pipeline is poised for a significant regulatory milestone. The company anticipates an FDA decision on its novel CAR‑T cell therapy, Anito‑cel, on 23 December 2026. Anito‑cel is intended to treat patients with refractory multiple myeloma, expanding Gilead’s therapeutic reach into a high‑need, high‑value indication. Kite, Gilead’s cellular‑therapy subsidiary, is also consolidating long‑term data on its already‑approved products, positioning the firm to leverage its platform across additional patient populations.
These developments are supported by Gilead’s robust financial footing: a market capitalization of $207 billion, a 52‑week high of $176.58, and a current share price of $166.89 (2026‑11‑05). Despite a negative price‑earnings ratio of –53.78—reflecting the company’s heavy investment in research and development—the market’s confidence in Gilead’s pipeline is evident from its sustained trading performance.
Strategically, the convergence of a highly adherent PrEP product and a forthcoming CAR‑T therapy signals a broadening of Gilead’s therapeutic portfolio. The company’s focus on HIV, liver disease, cardiovascular, and respiratory conditions, coupled with its cell‑therapy ambitions, positions Gilead to capture multiple high‑growth markets while maintaining its commitment to life‑changing innovations.
